Literature DB >> 14979998

Preparation of DNA dry powder for non-viral gene delivery by spray-freeze drying: effect of protective agents (polyethyleneimine and sugars) on the stability of DNA.

Jung-Hua Steven Kuo1, Robin Hwang.   

Abstract

This study investigates the feasibility of using the process of spray-freeze drying (SFD) to produce DNA dry powders for non-viral gene delivery. The effect of protective agents was assessed on the stability of DNA dry powders after SFD. The process of SFD had adverse effects on the tertiary structure of DNA with the protective agents of sucrose, trehalose and mannitol. With the protection of these sugars, a band corresponding to the linear form of DNA was observed during gel electrophoresis between the supercoiled form (SC) and the open circular (OC) form. On the contrary, excess cationic condensing polyethyleneimine (PEI), in conjunction with the above sugars, had the ability to provide protection for DNA from degradation after SFD. This is indicated by the reservation in SC and OC forms of DNA during agarose gel electrophoresis. The electrostatic forces between PEI polymer and DNA are critical for providing protection against various stresses generated by the process of SFD. Furthermore, on rehydration, the particle size and zeta potential of PEI/DNA complexes at weight ratios 3:1 of SFD dry powders were well maintained. Also, no transfection activity loss of PEI/DNA complexes at weight ratios 3:1 on NIH/3T3 cells was observed for reconstituted powders as compared with untreated control solutions. These results give a better understanding of preparing stable DNA dry powders by the process of SFD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14979998     DOI: 10.1211/0022357022494

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  14 in total

Review 1.  Particle engineering for pulmonary drug delivery.

Authors:  Albert H L Chow; Henry H Y Tong; Pratibhash Chattopadhyay; Boris Y Shekunov
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

Review 2.  Viral infections in lung transplant recipients.

Authors:  Pali Dedhiya Shah; John F McDyer
Journal:  Semin Respir Crit Care Med       Date:  2010-03-30       Impact factor: 3.119

3.  Delivery of pDNA Polyplexes to Bronchial and Alveolar Epithelial Cells Using a Mesh Nebulizer.

Authors:  Larissa Gomes Dos Reis; Maree Svolos; Lyn M Moir; Rima Jaber; Norbert Windhab; Paul M Young; Daniela Traini
Journal:  Pharm Res       Date:  2018-11-15       Impact factor: 4.200

4.  The effects of lyophilization on the physico-chemical stability of sirolimus liposomes.

Authors:  Saeed Ghanbarzadeh; Hadi Valizadeh; Parvin Zakeri-Milani
Journal:  Adv Pharm Bull       Date:  2013-02-07

5.  Chitosan-modified dry powder formulations for pulmonary gene delivery.

Authors:  Hao-Ying Li; James Birchall
Journal:  Pharm Res       Date:  2006-05-02       Impact factor: 4.580

6.  Pulmonary drug delivery strategies: A concise, systematic review.

Authors:  J S Patil; S Sarasija
Journal:  Lung India       Date:  2012-01

Review 7.  Nanomedicine in pulmonary delivery.

Authors:  Heidi M Mansour; Yun-Seok Rhee; Xiao Wu
Journal:  Int J Nanomedicine       Date:  2009-12-29

8.  Drying of a plasmid containing formulation: chitosan as a protecting agent.

Authors:  Nasir Mohajel; Abdolhossein R Najafabadi; Kayhan Azadmanesh; Alireza Vatanara; Mohsen Amini; Esmail Moazeni; Amirabbas Rahimi; Kambiz Gilani
Journal:  Daru       Date:  2012-09-10       Impact factor: 3.117

9.  Drying of a plasmid containing formulation: chitosan as a protecting agent.

Authors:  Nasir Mohajel; Abdolhossein R Najafabadi; Kayhan Azadmanesh; Mohsen Amini; Alireza Vatanara; Esmail Moazeni; Amirabbas Rahimi; Kambiz Gilani
Journal:  Daru       Date:  2012-09-03       Impact factor: 3.117

10.  Formulation of pH responsive peptides as inhalable dry powders for pulmonary delivery of nucleic acids.

Authors:  Wanling Liang; Philip C L Kwok; Michael Y T Chow; Patricia Tang; A James Mason; Hak-Kim Chan; Jenny K W Lam
Journal:  Eur J Pharm Biopharm       Date:  2013-05-20       Impact factor: 5.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.